HealthQuill Amgen Inc
The European Medicines Agency has granted a marketing authorisation in the EU for Amgen Inc.’s medicine for treating thyroid eye disease, according to a statement.
Drugs Medical Pharma

Amgen’s thyroid eye disease medicine gets EU market authorisation

HQ Team April 27, 2025: The European Medicines Agency has granted a marketing authorisation in the EU for Amgen Inc.’s medicine for treating.

Read More
Amgen Inc. will expand its Ohio biomanufacturing facility for $900 million, after a recent move to invest $1 billion to build a second manufacturing plant in Holly Springs, North Carolina, US.
Drugs Medical Pharma

Amgen to invest $900 million in Ohio biomanufacturing facility

HQ Team April 26, 2025: Amgen Inc. will expand its Ohio biomanufacturing facility for $900 million, after a recent move to invest $1 billion to.

Read More
Amgen Inc.’s treatment for adults living with immune-mediated inflammatory conditions was granted regulatory approval by the US Food and Drug Administration, according to a statement.
Drugs Health Medical

Amgen gets US approval to treat immunoglobulin G4-related disease 

HQ Team April 4, 2025: Amgen Inc.’s treatment for adults living with immune-mediated inflammatory conditions was granted regulatory approval by the US Food and.

Read More
Amgen Inc., a US biotechnology company, will set up a second drug manufacturing facility in North Carolina for $1 billion, according to a company statement.
Drugs Medical Pharma

Amgen Inc., to invest $1 billion to build a second plant in North Carolina

Amgen Inc., a US biotechnology company, will set up a second drug manufacturing facility in North Carolina for $1 billion, according to a.

Read More
Amgen Inc.’s experimental drug to treat patients suffering from a rare muscle-weakening disease, myasthenia gravis, has shown positive results in an end-stage trial and the California-based company has started talks with regulators for its approval.
Drugs Health Pharma

Amgen’s trial drug to fight autoimmune disorder improves patient outcomes

Amgen Inc.’s experimental drug to treat patients suffering from a rare muscle-weakening disease, myasthenia gravis, has shown positive results in an end-stage trial.

Read More
Amgen Inc., a US biotechnology company, completed the acquisition of Horizon Therapeutics Plc for $27.8 billion, gaining access to the Dublin-based firm’s two drugs that treat rare inflammatory diseases.
Drugs Health Pharma

Amgen completes $27.8b acquisition of Horizon Therapeutics

Amgen Inc., a US biotechnology company, completed the acquisition of Horizon Therapeutics Plc for $27.8 billion, gaining access to the Dublin-based firm’s two.

Read More